As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials
• By David Wallace
As Amgen’s current biosimilars portfolio recedes, bigger opportunities are on the horizon in the next wave • Source: Shutterstock 
